Pfizer 将来の成長
Future 基準チェック /06
Pfizerの収益と利益は、それぞれ年間3.7%と1.5%減少すると予測されています。EPS は年間2.6%で 減少すると予想されています。自己資本利益率は 3 年後に14.9%になると予測されています。
主要情報
-1.5%
収益成長率
-2.55%
EPS成長率
| Pharmaceuticals 収益成長 | 15.1% |
| 収益成長率 | -3.7% |
| 将来の株主資本利益率 | 14.91% |
| アナリストカバレッジ | Good |
| 最終更新日 | 27 Jul 2026 |
今後の成長に関する最新情報
Recent updates
Seeking Alpha • Jul 27
Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far
Summary I initiate Pfizer with a contrarian BUY rating and a $32 price target for 2026 Q3-Q4. PFE’s non-COVID portfolio demonstrates resilience, with Padcev, Vyndamax, and new launches driving operational growth despite patent cliffs. Padcev’s July 2026 approval expands its addressable market, while pipeline assets like Berobenatide and PF-08634404 offer additional upside. Valuation reflects patent-cliff risk, but strong cash flow, dividend support, and underappreciated pipeline provide a favorable risk/reward setup. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 13
PFE: Oncology And Obesity Pipeline Will Drive Post Patent Cliff Repricing
Pfizer's analyst price target has edged lower by about $0.80, reflecting updated models that factor in softer revenue expectations, slightly higher long term margin assumptions, and a reset of near term enthusiasm following multiple target cuts and a downgrade to Hold from several firms ahead of upcoming earnings catalysts. Analyst Commentary Recent research on Pfizer points to a mix of caution and optimism, with several firms trimming price targets while still seeing room for the stock to re-rate as execution on the core portfolio, business development and upcoming data readouts play through.
ナラティブ更新 • Jun 22
PFE: Oncology And Obesity Pipeline Progress Will Balance Patent Cliff Risks
Pfizer's analyst price target edges up by $1 to $26, as analysts point to a more balanced risk and reward profile supported by recent guidance commentary, oncology pipeline milestones, and updated views on longer term revenue and margin assumptions. Analyst Commentary Recent research coverage around Pfizer highlights a mix of upgraded ratings, modest price target increases and ongoing questions around specific product exposures and partnership choices.分析記事 • Jun 20
Pfizer (PFE) Stock Could Be 10% Undervalued After CFO Exit Raises Execution Questions
Pfizer (PFE) is back in focus after the company said Chief Financial Officer Dave Denton will leave in August, with long-time finance executive Cecile Guegan stepping in as interim CFO during the search for a successor. See our latest analysis for Pfizer. The CFO announcement comes as Pfizer shares trade at US$25.21, with the stock down over the past quarter but posting a 12.52% total shareholder return over the last year. This suggests that shorter term momentum has cooled even as income and...ナラティブ更新 • Jun 08
PFE: Oncology And Obesity Pipeline Will Support Post Patent Cliff Repricing
Narrative update Pfizer's analyst price targets have inched higher, with a recent move such as Wolfe Research lifting its view to $26 from $25 as analysts factor in elements like the five-year sales outlook and extended Vyndamax exclusivity, while also accounting for COVID-related uncertainty in their updated assumptions. Analyst Commentary Recent Street commentary on Pfizer centers on two themes investors should keep in mind: how analysts are framing post COVID revenue visibility and how legal and partnership developments may affect long term cash flow and valuation support.
ナラティブ更新 • May 25
PFE: Obesity And Oncology Pipeline Progress Will Drive Long-Term Upside Potential
Analysts have nudged Pfizer's implied fair value slightly higher to about $29.19 per share, reflecting a series of mostly modest price target increases, including Wolfe Research's move to $26. This comes alongside updated views on long term sales, COVID uncertainty, patent settlements around Vyndamax, and the recent Veppanu licensing, as well as GLP-1 and oncology pipeline commentary.ナラティブ更新 • May 03
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook
Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.ナラティブ更新 • Apr 19
PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing
Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.ナラティブ更新 • Apr 05
PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating
Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.ナラティブ更新 • Mar 22
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook
Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.ナラティブ更新 • Mar 08
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade
Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.ナラティブ更新 • Feb 21
PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating
Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.ナラティブ更新 • Feb 07
PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating
Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.ナラティブ更新 • Jan 24
PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares
Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.ナラティブ更新 • Jan 10
PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential
Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.分析記事 • Jan 08
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...ナラティブ更新 • Dec 25
PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead
Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.分析記事 • Dec 18
Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43
The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...ナラティブ更新 • Dec 11
PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating
Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.ナラティブ更新 • Nov 13
PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts
Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 54,940 | 9,468 | 15,911 | 16,540 | 21 |
| 12/31/2027 | 59,367 | 10,279 | 17,755 | 17,452 | 24 |
| 12/31/2026 | 61,743 | 10,633 | 20,597 | 18,327 | 25 |
| 3/29/2026 | 63,315 | 7,479 | 9,483 | 11,984 | N/A |
| 12/31/2025 | 62,579 | 7,746 | 9,075 | 11,704 | N/A |
| 9/28/2025 | 62,785 | 9,797 | 10,376 | 13,077 | N/A |
| 6/29/2025 | 63,833 | 10,728 | 12,438 | 15,188 | N/A |
| 3/30/2025 | 62,464 | 7,867 | 11,220 | 13,989 | N/A |
| 12/31/2024 | 63,627 | 8,020 | 9,835 | 12,744 | N/A |
| 9/29/2024 | 60,433 | 4,274 | 8,227 | 11,263 | N/A |
| 6/30/2024 | 56,223 | -2,593 | 4,810 | 8,005 | N/A |
| 3/31/2024 | 55,946 | -288 | 5,106 | 8,578 | N/A |
| 12/31/2023 | 59,554 | 2,134 | 4,793 | 8,700 | N/A |
| 10/1/2023 | 69,274 | 10,469 | 8,178 | 12,042 | N/A |
| 7/2/2023 | 78,420 | 21,494 | 10,665 | 14,560 | N/A |
| 4/2/2023 | 93,154 | 29,035 | 20,206 | 23,938 | N/A |
| 12/31/2022 | 101,175 | 31,366 | 26,031 | 29,267 | N/A |
| 10/2/2022 | 99,878 | 29,953 | 23,362 | 26,599 | N/A |
| 7/3/2022 | 101,275 | 29,481 | 28,440 | 31,454 | N/A |
| 4/3/2022 | 92,433 | 25,410 | 31,783 | 34,583 | N/A |
| 12/31/2021 | 81,288 | 22,413 | 29,869 | 32,580 | N/A |
| 10/3/2021 | 68,877 | 19,485 | 29,769 | 32,291 | N/A |
| 7/4/2021 | 55,119 | 12,236 | 21,141 | 23,552 | N/A |
| 4/4/2021 | 46,084 | 9,032 | 13,477 | 15,808 | N/A |
| 12/31/2020 | 41,651 | 6,630 | 12,177 | 14,403 | N/A |
| 9/27/2020 | 32,334 | 212 | 10,512 | 12,547 | N/A |
| 6/28/2020 | 34,737 | 6,977 | 12,777 | 14,967 | N/A |
| 3/29/2020 | 38,137 | 9,427 | 11,702 | 14,023 | N/A |
| 12/31/2019 | 40,905 | 10,707 | N/A | 12,588 | N/A |
| 9/29/2019 | 53,039 | 16,211 | N/A | 13,557 | N/A |
| 6/30/2019 | 53,656 | 12,638 | N/A | 14,306 | N/A |
| 3/31/2019 | 53,859 | 11,464 | N/A | 15,542 | N/A |
| 12/31/2018 | 40,825 | 3,824 | N/A | 15,827 | N/A |
| 9/30/2018 | 53,373 | 23,808 | N/A | 18,178 | N/A |
| 7/1/2018 | 53,244 | 22,545 | N/A | 17,808 | N/A |
| 4/1/2018 | 52,673 | 21,746 | N/A | 17,201 | N/A |
| 12/31/2017 | 52,546 | 21,305 | N/A | 16,802 | N/A |
| 10/1/2017 | 52,471 | 9,791 | N/A | 15,463 | N/A |
| 7/2/2017 | 52,347 | 8,308 | N/A | 15,311 | N/A |
| 4/2/2017 | 52,598 | 7,281 | N/A | 15,677 | N/A |
| 12/31/2016 | 52,824 | 7,198 | N/A | 16,192 | N/A |
| 10/2/2016 | 53,243 | 6,270 | N/A | 15,049 | N/A |
| 7/3/2016 | 52,286 | 7,036 | N/A | 15,332 | N/A |
| 4/3/2016 | 50,992 | 7,615 | N/A | 15,816 | N/A |
| 12/31/2015 | 48,851 | 6,948 | N/A | 14,688 | N/A |
| 9/27/2015 | 47,922 | 8,366 | N/A | 15,188 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: PFEの収益は今後 3 年間で減少すると予測されています (年間-1.5% )。
収益対市場: PFEの収益は今後 3 年間で減少すると予測されています (年間-1.5% )。
高成長収益: PFEの収益は今後 3 年間で減少すると予測されています。
収益対市場: PFEの収益は今後 3 年間で減少すると予想されています (年間-3.7% )。
高い収益成長: PFEの収益は今後 3 年間で減少すると予測されています (年間-3.7% )。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: PFEの 自己資本利益率 は、3年後には低くなると予測されています ( 14.9 %)。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/29 07:09 |
| 終値 | 2026/07/29 00:00 |
| 収益 | 2026/03/29 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Pfizer Inc. 25 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。44
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |